Scholarlink

Background <p>Fibrin nanoparticles, being non-immunogenic, non-toxic, and biodegradable, can serve as a suitable drug-delivery system for selectively targeting tumors.</p> Main body of the abstract <p>In this review, we summarize the current state of the literature on fibrin-based nanoplatforms, emphasizingtheir preparation and conjugation strategies, as well as their applications in tumor therapy. A comprehensive search was performed in the available databases, including PubMed, Semantic Scholar, and Web of Science. Our main findings are that the self-assembled fibrin nanoplatform enables programmable chemotherapeutic release kinetics, with increased bioavailability and enhanced passive and active tumor targeting. This reduces systemic toxicity owing to the biocompatibility of fibrin polymers designed for clinical use. Furthermore, experimental data highlight the successful implementation of fibrin nanoplatforms combined with chemotherapeutics and immunotherapeutics to improve therapeutic efficacy. The review also explains the difficulties of scalability and the need for a comprehensive clinical dataset.</p> Conclusion <p>This review highlights fibrin biopolymer nanoplatforms as versatile modules for carcinoma therapy, potentially stimulating further research and clinical advancement. Fibrin biopolymer nanoplatforms have numerous applications in pharmaceutical and clinical theranostics as drug-delivery systems for various carcinomas.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fibrin-assisted nanocarrier systems: innovations and challenges in targeted carcinoma drug delivery

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月23日

查看全文
  • Dipti Sukumaran Chirakara,
  • Shriya Ravindranath Lotlikar,
  • Nageswara Rao Dunna,
  • Sivaramakrishnan Venkatabalasubramanian

摘要

Background

Fibrin nanoparticles, being non-immunogenic, non-toxic, and biodegradable, can serve as a suitable drug-delivery system for selectively targeting tumors.

Main body of the abstract

In this review, we summarize the current state of the literature on fibrin-based nanoplatforms, emphasizingtheir preparation and conjugation strategies, as well as their applications in tumor therapy. A comprehensive search was performed in the available databases, including PubMed, Semantic Scholar, and Web of Science. Our main findings are that the self-assembled fibrin nanoplatform enables programmable chemotherapeutic release kinetics, with increased bioavailability and enhanced passive and active tumor targeting. This reduces systemic toxicity owing to the biocompatibility of fibrin polymers designed for clinical use. Furthermore, experimental data highlight the successful implementation of fibrin nanoplatforms combined with chemotherapeutics and immunotherapeutics to improve therapeutic efficacy. The review also explains the difficulties of scalability and the need for a comprehensive clinical dataset.

Conclusion

This review highlights fibrin biopolymer nanoplatforms as versatile modules for carcinoma therapy, potentially stimulating further research and clinical advancement. Fibrin biopolymer nanoplatforms have numerous applications in pharmaceutical and clinical theranostics as drug-delivery systems for various carcinomas.